Oppenheimer & Co. Inc. Boosts Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Oppenheimer & Co. Inc. lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 41.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 63,424 shares of the company’s stock after purchasing an additional 18,531 shares during the period. Oppenheimer & Co. Inc.’s holdings in TransMedics Group were worth $3,954,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TMDX. Taylor Frigon Capital Management LLC acquired a new position in TransMedics Group during the 4th quarter worth $1,535,000. IFP Advisors Inc boosted its stake in shares of TransMedics Group by 732.3% in the 4th quarter. IFP Advisors Inc now owns 6,783 shares of the company’s stock valued at $423,000 after buying an additional 5,968 shares during the period. Arcadia Investment Management Corp MI acquired a new position in shares of TransMedics Group during the fourth quarter worth about $72,000. Handelsbanken Fonder AB grew its position in shares of TransMedics Group by 27.2% during the fourth quarter. Handelsbanken Fonder AB now owns 81,900 shares of the company’s stock worth $5,106,000 after buying an additional 17,500 shares in the last quarter. Finally, Global Retirement Partners LLC increased its stake in shares of TransMedics Group by 4,132.5% during the fourth quarter. Global Retirement Partners LLC now owns 3,259 shares of the company’s stock worth $203,000 after buying an additional 3,182 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Piper Sandler lowered their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $76.32 on Friday. The stock’s 50-day moving average is $67.81 and its two-hundred day moving average is $101.20. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 81.19 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.